---
created: 2025-04-13
updated: 2025-04-13T10:52
id: Qd4TvaAIq-
specialty: pharmaco
specialty_id: 262
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::01-hemostasis::02-platelet-activation
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::01-hemostasis::06-antiplatelet-drugs
  - "source/ak-step1-v11:": 
  - theme/b&b::11-hematology::01-hemostasis::07-anticoagulants
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::07-adp-receptor-inhibitors
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::13-hematology-oncology::11-hemostasis
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::17-hem/onc-pharm::adp-receptors-inhibitors
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::10-heme::adp-receptor-inhibitors
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::03-blood-&-inflammation::01-anticoagulants-&-thrombolytics::03-antiplatelet-agents
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield"
type: flashcard
---

# Question
What class of anti-platelet drugs may cause TTP as an adverse effect?   **ADP receptor inhibitors**

---

# Answer
- aka P2Y12 inhibitors  Ex -grel suffix /  ticlopidine (strongest association with)